BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

Enrollment exceeds 60% of required number of patients in SERENITY At-Home pivotal Phase 3 safety trial evaluating 200 patients for acute treatment of agitation associated with bipolar disorders or schizophrenia The Company is continuing to supply IGALMI (dexmedetomidine) sublingual film to current and future patients and providers through existing distribution channels, with minimal commercial support. Equity Financing Closed $14 million equity financing and strengthened cash position to approximately$35 m ...